ECSP21067104A - Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas - Google Patents

Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas

Info

Publication number
ECSP21067104A
ECSP21067104A ECSENADI202167104A ECDI202167104A ECSP21067104A EC SP21067104 A ECSP21067104 A EC SP21067104A EC SENADI202167104 A ECSENADI202167104 A EC SENADI202167104A EC DI202167104 A ECDI202167104 A EC DI202167104A EC SP21067104 A ECSP21067104 A EC SP21067104A
Authority
EC
Ecuador
Prior art keywords
amorphous
formulations
compound
fluoro
preparing
Prior art date
Application number
ECSENADI202167104A
Other languages
English (en)
Inventor
Mandar Dali
Akm Uddin
Onkar Vaze
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of ECSP21067104A publication Critical patent/ECSP21067104A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción en general se relaciona con formas amorfas de compuestos que tienen solubilidad acuosa mejorada y velocidades de disolución y dispersiones sólidas amorfas y formulaciones farmacéuticas orales de las mismas, y a procesos para preparar las mismas. La presente descripción se relaciona específicamente con formas amorfas de 5-fluoro-2-(6-fluoro-2-metil-1H-bencimidazol-1-il)-N-[4-(trifluorometil)fenil]pirimidin-4,6-diamina y dispersiones sólidas amorfas y formulaciones farmacéuticas orales de las mismas, y a procesos para preparar las mismas.
ECSENADI202167104A 2019-03-11 2021-09-09 Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas ECSP21067104A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962816402P 2019-03-11 2019-03-11

Publications (1)

Publication Number Publication Date
ECSP21067104A true ECSP21067104A (es) 2021-11-18

Family

ID=70166162

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202167104A ECSP21067104A (es) 2019-03-11 2021-09-09 Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas

Country Status (20)

Country Link
US (1) US20220185795A1 (es)
EP (1) EP3938368B1 (es)
JP (1) JP2022524424A (es)
KR (1) KR20210151061A (es)
CN (1) CN113853374B (es)
AU (1) AU2020235825A1 (es)
BR (1) BR112021017353A2 (es)
CA (1) CA3131801A1 (es)
CL (1) CL2021002365A1 (es)
CO (1) CO2021011836A2 (es)
EA (1) EA202192167A1 (es)
EC (1) ECSP21067104A (es)
HU (1) HUE062796T2 (es)
IL (1) IL286163A (es)
MX (1) MX2021010906A (es)
PE (1) PE20212270A1 (es)
PL (1) PL3938368T3 (es)
SG (1) SG11202109503TA (es)
WO (1) WO2020185648A1 (es)
ZA (1) ZA202106437B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12015501130B1 (en) * 2012-11-21 2023-01-27 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
JP2021535198A (ja) 2018-08-17 2021-12-16 ピーティーシー セラピューティクス, インコーポレイテッド 膵臓癌を治療する方法
AU2020227748A1 (en) * 2019-02-28 2021-09-16 Ptc Therapeutics, Inc. Method for treating a multiple myeloma
CA3134648A1 (en) * 2019-03-27 2020-10-01 Ptc Therapeutics, Inc. Combinations useful in a method for treating sarcoma
EP4065090A1 (en) * 2019-11-26 2022-10-05 Ikena Oncology, Inc. Ahr inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12015501130B1 (en) * 2012-11-21 2023-01-27 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
NZ708272A (en) * 2013-01-22 2020-07-31 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
WO2016155655A1 (zh) * 2015-04-03 2016-10-06 上海瑛派药业有限公司 Parp抑制剂固体药物剂型及其应用
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide

Also Published As

Publication number Publication date
ZA202106437B (en) 2025-01-29
HUE062796T2 (hu) 2023-12-28
PE20212270A1 (es) 2021-11-30
MX2021010906A (es) 2021-10-01
SG11202109503TA (en) 2021-09-29
EA202192167A1 (ru) 2022-01-12
CN113853374B (zh) 2025-02-28
CA3131801A1 (en) 2020-09-17
CN113853374A (zh) 2021-12-28
EP3938368B1 (en) 2023-06-07
IL286163A (en) 2021-10-31
US20220185795A1 (en) 2022-06-16
BR112021017353A2 (pt) 2021-11-16
WO2020185648A1 (en) 2020-09-17
CO2021011836A2 (es) 2021-12-10
PL3938368T3 (pl) 2023-12-27
EP3938368A1 (en) 2022-01-19
KR20210151061A (ko) 2021-12-13
AU2020235825A1 (en) 2021-09-30
JP2022524424A (ja) 2022-05-02
CL2021002365A1 (es) 2022-04-22

Similar Documents

Publication Publication Date Title
CL2021002365A1 (es) Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas
MX392634B (es) Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta y un proceso para prepararlo
CY1124848T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν azd9291
EA201892007A1 (ru) 3-дезоксипроизводное и фармацевтические композиции на его основе
JO3430B1 (ar) مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
NZ631100A (en) Soft chewable pharmaceutical products
SA521421645B1 (ar) بيرولينات إندماجية تعمل كمثبطات بروتياز نوعي لأوبيكويتين 30
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201591531A1 (ru) Ингибиторы аргининметилтрансферазы и их применения
MX374541B (es) Sales de clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino) pirimidin-4-il)benzamida.
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
MX2017010945A (es) Preparacion solida.
EA201691538A1 (ru) Способ получения солей вортиоксетина
EA201692300A1 (ru) Производные карбоксамида
ECSP11011286A (es) Formulaciones orales sólidas de una pirido-pirimidinona
CY1125052T1 (el) Κρυσταλλικες μορφες
AR080127A1 (es) Inhibidores de la amida hidrolasa de acidos grasos, composiciones farmaceuticas y sus usos
MX359556B (es) Acido 2-[5-[n-(4-fluorofenil)carbamoíl]pirimidin-2-ilsulfanilmetil ]-4-(trifluorometoxi)fenil]borónico.
EA201990093A1 (ru) Двухкомпонентная композиция
MX382199B (es) Formulacion farmaceutica.
MX381175B (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
MX377314B (es) Sal de un derivado de cefalosporina, forma sólida cristalina del mismo y método para su producción.
WO2016165205A8 (zh) 一种新型的bcr-abl激酶抑制剂
CL2017002180A1 (es) Formas cristalinas de un compuesto de pirrolopiridina
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida